Boundless Bio (BOLD) Cash from Operations (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Cash from Operations of 15000000.0 for Q1 2026, down 3.23% year-over-year from 15501422.48 in Q1 2025, and down 47.84% quarter-over-quarter from 10146000.0 in Q4 2025.
Boundless Bio (BOLD) Cash from Operations (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Cash from Operations for 4 consecutive years, with 15000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 3.23% year-over-year to 15000000.0; the TTM figure through Mar 2026 stood at 47170000.0 (up 20.85% YoY), while the FY2025 annual figure was 46700000.0, up 23.24% from the prior year.
- Cash from Operations eased to 15000000.0 in Q1 2026 per BOLD's latest filing, from 10146000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 10146000.0 in Q4 2025 and bottomed at 16236000.0 in Q2 2024.
- Historically, Cash from Operations has averaged 13030461.54 across 4 years, with a median of 12189000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 49.09% — and 2025, when it surged 34.81%.
- Boundless Bio's Cash from Operations stood at 11686000.0 in 2023, then sank by 33.18% to 15563000.0 in 2024, then jumped by 34.81% to 10146000.0 in 2025, then slumped by 47.84% to 15000000.0 in 2026.
- Business Quant data shows BOLD's Cash from Operations at 15000000.0 in Q1 2026, 10146000.0 in Q4 2025, and 10154000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 728.46 Mn |
| 10 | Boundless Bio | 66.79 Mn | 66.79 Mn | - | -20.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.95 Mn |
| Jun 30, 2026 | -20.95 Mn |
| Mar 31, 2026 | -15.00 Mn |
| Mar 31, 2026 | -15.00 Mn |
| Dec 31, 2025 | -10.15 Mn |
| Dec 31, 2025 | -10.15 Mn |
| Sep 30, 2025 | -10.15 Mn |
| Sep 30, 2025 | -10.15 Mn |
| Jun 30, 2025 | -11.87 Mn |
| Jun 30, 2025 | -11.87 Mn |
| Mar 31, 2025 | -14.53 Mn |
| Mar 31, 2025 | -14.53 Mn |
| Dec 31, 2024 | -15.56 Mn |
| Dec 31, 2024 | -15.56 Mn |
| Sep 30, 2024 | -13.27 Mn |
| Sep 30, 2024 | -13.27 Mn |
| Jun 30, 2024 | -16.24 Mn |
| Jun 30, 2024 | -16.24 Mn |
| Mar 31, 2024 | -15.78 Mn |
| Mar 31, 2024 | -15.78 Mn |